Alto Neuroscience (NYSE:ANRO) Rating Increased to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Alto Neuroscience from a “sell” to a “hold” rating, adding to a generally constructive analyst backdrop for the stock.
• Other firms remain mostly bullish: seven analysts rate ANRO a Buy, with a consensus rating of Moderate Buy and an average price target of $35.13.
• Alto Neuroscience reported a narrower-than-expected quarterly loss of ($0.45) EPS versus the $0.56 estimate, while the stock recently traded at $24.26 after reaching a 52-week high of $28.44.

Alto Neuroscience (NYSE:ANRO - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday.

Several other research firms also recently weighed in on ANRO. BTIG Research boosted their target price on Alto Neuroscience from $27.00 to $28.00 and gave the company a "buy" rating in a research report on Tuesday, February 17th. Bank of America assumed coverage on shares of Alto Neuroscience in a research note on Tuesday. They set a "buy" rating and a $35.00 price objective for the company. Wedbush cut their price objective on shares of Alto Neuroscience from $22.00 to $21.00 and set a "neutral" rating on the stock in a research report on Thursday, April 2nd. HC Wainwright reissued a "buy" rating and issued a $50.00 target price on shares of Alto Neuroscience in a research note on Thursday, April 2nd. Finally, Robert W. Baird lowered their target price on shares of Alto Neuroscience from $41.00 to $38.00 and set an "outperform" rating for the company in a report on Thursday, April 2nd. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Alto Neuroscience presently has an average rating of "Moderate Buy" and a consensus price target of $35.13.

Get Alto Neuroscience SMS alerts:

Sign Up

Alto Neuroscience Stock Performance

NYSE:ANRO opened at $24.26 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.69. Alto Neuroscience has a 1 year low of $2.15 and a 1 year high of $28.44. The stock's 50 day simple moving average is $22.78 and its two-hundred day simple moving average is $18.00. The company has a market cap of $775.08 million, a price-to-earnings ratio of -11.13 and a beta of 1.62.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.11. As a group, equities analysts anticipate that Alto Neuroscience will post -2.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

A number of large investors have recently bought and sold shares of the business. Commodore Capital LP bought a new position in Alto Neuroscience in the 4th quarter valued at $32,453,000. Perceptive Advisors LLC lifted its position in shares of Alto Neuroscience by 1,048.5% during the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company's stock worth $31,762,000 after purchasing an additional 1,629,027 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Alto Neuroscience by 161.6% during the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company's stock valued at $44,233,000 after purchasing an additional 1,535,000 shares during the period. Vivo Capital LLC purchased a new stake in shares of Alto Neuroscience during the fourth quarter valued at $18,433,000. Finally, Ikarian Capital LLC grew its holdings in shares of Alto Neuroscience by 368.2% in the fourth quarter. Ikarian Capital LLC now owns 515,000 shares of the company's stock worth $9,167,000 after purchasing an additional 405,000 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.